# US 2013/0156749 A1 · Pretreatment or post exposure treatment for exposure to a toxic substance by pulmonary delivery (inhaler) of a bioscavenger

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0156749 A1
- Document ID: US20130156749A1
- Status: Published application
- Kind: A1
- Application number: 13/769,799
- Filed: 2013-02-18
- Published: 2013-06-20
- Earliest claimed: 2002-11-13
- Inventors: Yvonne Rosenberg
- Web page: https://patentgrep.com/patent/US20130156749A1

## CPC

- A61K 38/465: {acting on ester bonds (3.1), e.g. lipases, ribonucleases}
- A61K 9/007: {Pulmonary tract; Aromatherapy}
- A61K 9/0073: {Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy; (nasal sprays A61K9/0043; inhalation of vapours of volatile or heated drugs, e.g. essential oils or nicotine, A61K9/007; devices A61M)}
- A61K 9/0075: {for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles}
- A61K 9/0078: {for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions}
- A61K 31/215: of carboxylic acids
- A61K 31/66: Phosphorus compounds
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 39/02: Antidotes
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12Y 301/01007: Acetylcholinesterase (3.1.1.7)
- C12Y 301/01008: Cholinesterase (3.1.1.8), i.e. butyrylcholine-esterase
- Y10S 588/901: Compositions
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Y: ENZYMES
- Y10S: TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS

## Abstract

The present invention relates to a treatment by pulmonary delivery of a bioscavenger to animals as an effective antidote to prevent toxicity produced by exposure of an animal to nerve agents and other toxic substances.

## Claims

### Claim 1

A method of treating a human for exposure to a neurotoxin which comprises administering by inhalation to the lungs of said human an effective amount of a bioscavenger molecule that detoxifies said neurotoxin, wherein said neurotoxin is a nerve agent or a pesticide, and wherein said bioscavenger molecule is a paraoxonase, an organophosphate hydrolase, an organophosphorous acid anhydrolase or a parathion hydrolase.

### Claim 2 (depends on 1)

The method of claim 1, which comprises administering by inhalation said bioscavenger molecule prior to exposure to said neurotoxin.

### Claim 3 (depends on 1)

The method of claim 1, wherein said bioscavenger molecule is administered by inhalation after exposure to said neurotoxin.

### Claim 4 (depends on 1)

The method of claim 1, wherein said neurotoxin is an organophosphate.

### Claim 5 (depends on 1)

The method of claim 1, wherein said bioscavenger molecule is a human enzyme.

### Claim 6 (depends on 1)

The method of claim 1, wherein said bioscavenger molecule is administered by inhalation in powder form.

### Claim 7 (depends on 1)

The method of claim 1, wherein said bioscavenger molecule is administered by inhalation in liquid form.

### Claim 8 (depends on 4)

The method of claim 4, wherein said organophosphate is selected from the group consisting of sarin (O-isopropyl-methylphosphonofluoridate), VX (ethyl-S-2-diisopropylaminoethyl-phosphano-thiolate), MEPQ (7-(methylethoxyphosphinyloxy)-1-methylquinolinium iodide), soman (pinacolylmethyl-phosphonofluoridate), DFP (diisopylfluorophosphate paraoxon), malathion and parathion.

### Claim 9 (depends on 1)

The method of claim 1, wherein said bioscavenger molecule is a native molecule.

### Claim 10 (depends on 1)

The method of claim 1, wherein said bioscavenger molecule is a recombinant molecule.

### Claim 11 (depends on 10)

The method of claim 10, wherein said recombinant molecule is produced in vitro in mammalian or insect cells.

### Claim 12 (depends on 10)

The method of claim 10, wherein said recombinant molecule is glycosylated.

### Claim 13 (depends on 11)

The method of claim 11, wherein said mammalian cells are Chinese Hamster Ovary (CHO) cells.

### Claim 14 (depends on 10)

The method of claim 10, wherein said recombinant molecule is produced in vivo in a transgenic plant.

### Claim 15 (depends on 10)

The method of claim 10, wherein said recombinant molecule is produced in vivo in a transgenic non-human animal.

### Claim 16 (depends on 1)

The method of claim 1, which further comprises administering with said bioscavenger molecule, a permeation enhancer.

### Claim 17 (depends on 16)

The method of claim 16, wherein said permeation enhancer is selected from the group consisting of oleic acid, dimethyl-b-cyclodextrin, citric acid and polyethylene glycol.

### Claim 18 (depends on 7)

The method of claim 7, wherein said liquid form comprises an aerosol.

### Claim 19 (depends on 6)

The method of claim 6, wherein said powder form comprises an aerosol.

### Claim 20 (depends on 12)

The method of claim 12, wherein glycosylation comprises sialylation.